COVID-19 and diabetes mellitus: a review of the incidence, pathophysiology and management of diabetes during the pandemic

References

• Coronavirus resource center: Johns Hopkins University of Medicine. https://coronavirus.jhu.edu/map.html
   Google Scholar
• Lim S, Bae JH, Kwon HS, et al. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol. 2021 Jan;17(1):11–30.
   PubMed Web of Science ®Google Scholar
• Muralidar S, Ambi SV, Sekaran S, et al. The emergence of COVID-19 as a global pandemic: understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2. Biochimie. 2020;179:85–100.
   PubMed Web of Science ®Google Scholar
• Atkinson MA, Powers AC. Distinguishing the real from the hyperglycaemia: does COVID-19 induce diabetes? Lancet Diabetes Endocrinol. 2021 Jun;9(6):328–329.
   PubMed Web of Science ®Google Scholar
• Lotfy MA, Shama AA. Intensive insulin therapy improves the survival probability of non-diabetic COVID-19 patients presenting with acute hyperglycemia. Egypt J Anaesth. 2022;38(1):211–219.
   Web of Science ®Google Scholar
• Wu L, Girgis CM, Cheung NW. COVID‐19 and diabetes: insulin requirements parallel illness severity in critically unwell patients. Clin Endocrinol (Oxf). 2020;93(4):390–393.
   PubMed Web of Science ®Google Scholar
• Khunti K, Del Prato S, Mathieu C, et al. COVID-19, hyperglycemia, and new-onset diabetes. Diabetes Care. 2021 Dec;44(12):2645–2655.
   PubMed Web of Science ®Google Scholar
• Núñez A, Sreeganga SD, Ramaprasad A. Access to Healthcare during COVID-19. Int J Environ Res Public Health. 2021;18(6):2980.
   PubMed Web of Science ®Google Scholar
• Vellanki P, Umpierrez GE. Diabetic ketoacidosis risk during the COVID-19 pandemic. Lancet Diabetes Endocrinol. 2021 Oct;9(10):643–644.
   PubMed Web of Science ®Google Scholar
• Nalini R, Ozer K, Maldonado M, et al. Presence or absence of a known diabetic ketoacidosis precipitant defines distinct syndromes of “A-β+” ketosis-prone diabetes based on long-term β-cell function, human leukocyte antigen class II alleles, and sex predilection. Metabolism. 2010 Oct;59(10):1448–1455.
   PubMed Web of Science ®Google Scholar
• Jamison DA Jr., Anand Narayanan S, Trovao NS, et al. A comprehensive SARS-CoV-2 and COVID-19 review, Part 1: intracellular overdrive for SARS-CoV-2 infection. Eur J Hum Genet. 2022 Aug;30(8):889–898.
   PubMed Web of Science ®Google Scholar
• Yao H, Song Y, Chen Y, et al. Molecular Architecture of the SARS-CoV-2 Virus. Cell. 2020 Oct 29;183(3):730–738 e13.
   PubMed Web of Science ®Google Scholar
• Letko M, Munster V. Functional assessment of cell entry and receptor usage for lineage B beta-coronaviruses, including 2019-nCoV. bioRxiv. 2020 Jan;22.
   Google Scholar
• Santos A, Magro DO, Evangelista-Poderoso R, et al. Diabetes, obesity, and insulin resistance in COVID-19: molecular interrelationship and therapeutic implications. Diabetol Metab Syndr. 2021 Mar 1;13(1):23.
   PubMed Web of Science ®Google Scholar
• Patel VB, Clarke N, Wang Z, et al. Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: a positive feedback mechanism in the RAS. J Mol Cell Cardiol. 2014;66:167–176.
   PubMed Web of Science ®Google Scholar
• Lambert DW, Yarski M, Warner FJ, et al. Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem. 2005 Aug 26;280(34):30113–30119.
   PubMed Web of Science ®Google Scholar
• Montezano AC, Nguyen Dinh Cat A, FJ R, et al. Angiotensin II and vascular injury. Curr Hypertens Rep. 2014 Jun;16(6):431.
   PubMed Web of Science ®Google Scholar
• Tomar B, Anders HJ, Desai J, et al. Neutrophils and neutrophil extracellular traps drive necroinflammation in COVID-19. Cells. 2020 2;9(6):Jun.
   Web of Science ®Google Scholar
• Zuo Y, Yalavarthi S, Shi H, et al. Neutrophil extracellular traps in COVID-19. JCI Insight. 2020 Jun 4;5:11.
   Web of Science ®Google Scholar
• Wong SL, Demers M, Martinod K, et al. Diabetes primes neutrophils to undergo NETosis, which impairs wound healing. Nat Med. 2015 Jul;21(7):815–819.
   PubMed Web of Science ®Google Scholar
• Rahmati M, Keshvari M, Mirnasuri S, et al. The global impact of COVID-19 pandemic on the incidence of pediatric new-onset type 1 diabetes and ketoacidosis: a systematic review and meta-analysis. J Med Virol. 2022 Nov;94(11):5112–5127.
   PubMed Web of Science ®Google Scholar
• Kamrath C, Rosenbauer J, Eckert AJ, et al. Incidence of Type 1 diabetes in children and adolescents during the COVID-19 pandemic in Germany: results from the DPV registry. Diabetes Care. 2022 Aug 1;45(8):1762–1771.
   PubMed Web of Science ®Google Scholar
• Vlad A, Serban V, Timar R, et al. Increased incidence of type 1 diabetes during the COVID-19 pandemic in Romanian children. Medicina (B Aires). 2021;57(9):973.
   Google Scholar
• Kendall EK, Olaker VR, Kaelber DC, et al. Association of SARS-CoV-2 infection with new-onset type 1 diabetes among pediatric patients from 2020 to 2021. JAMA Network Open. 2022;5(9):e2233014.
   PubMed Web of Science ®Google Scholar
• Shulman R, Cohen E, Stukel TA, et al. Examination of trends in diabetes incidence among children during the COVID-19 pandemic in Ontario, Canada, From March 2020 to September 2021. JAMA Network Open. 2022;5(7):e2223394.
   PubMed Web of Science ®Google Scholar
• Barrett CE, Koyama AK, Alvarez P, et al. Risk for Newly diagnosed diabetes >30 days after SARS-CoV-2 infection among persons aged <18 years - United States, March 1, 2020-June 28, 2021. MMWR Morb Mortal Wkly Rep. 2022 Jan 14;71(2):59–65.
   PubMed Web of Science ®Google Scholar
• Xie Y, Al-Aly Z. Risks and burdens of incident diabetes in long COVID: a cohort study. Lancet Diabetes Endocrinol. 2022;10(5):311–321.
   PubMed Web of Science ®Google Scholar
• Rathmann W, Kuss O, Kostev K. Incidence of newly diagnosed diabetes after Covid-19. Diabetologia. 2022;65(6):949–954.
   PubMed Web of Science ®Google Scholar
• La Verde M, Torella M, Riemma G, et al. Incidence of gestational diabetes mellitus before and after the Covid‐19 lockdown: a retrospective cohort study. J Obstetrics Gynaecol Res. 2022;48(5):1126–1131.
   PubMed Web of Science ®Google Scholar
• Gaba R, Balasubramanyam A. Covid-19: a new cause of “provoked” A-beta+ ketosis-prone diabetes. J Diabetes Complications. 2022 Apr;36(4):108147.
   PubMed Web of Science ®Google Scholar
• Maldonado M, Hampe CS, Gaur LK, et al. Ketosis-prone diabetes: dissection of a heterogeneous syndrome using an immunogenetic and beta-cell functional classification, prospective analysis, and clinical outcomes. J Clin Endocrinol Metab. 2003 Nov;88(11):5090–5098.
   PubMed Web of Science ®Google Scholar
• Balasubramanyam A. Syndromes of ketosis-prone diabetes. Trans Am Clin Climatol Assoc. 2019;130:145–155.
   PubMedGoogle Scholar
• Gupta RD, Atri A, Mondal S, et al. Characterizing progressive beta-cell recovery after new-onset DKA in COVID-19 provoked A-beta+ KPD (ketosis-prone diabetes): a prospective study from Eastern India. J Diabetes Complications. 2022 Mar;36(3):108100.
   PubMed Web of Science ®Google Scholar
• Pasquel FJ, Messler J, Booth R, et al. Characteristics of and mortality associated with diabetic ketoacidosis among US patients hospitalized with or without COVID-19. JAMA Network Open. 2021 Mar 1;4(3):e211091.
   PubMed Web of Science ®Google Scholar
• Misra S, Barron E, Vamos E, et al. Temporal trends in emergency admissions for diabetic ketoacidosis in people with diabetes in England before and during the COVID-19 pandemic: a population-based study. Lancet Diabetes Endocrinol. 2021 Oct;9(10):671–680.
   PubMed Web of Science ®Google Scholar
• Kamrath C, Mönkemöller K, Biester T, et al. Ketoacidosis in children and adolescents with newly diagnosed type 1 diabetes during the COVID-19 pandemic in Germany. JAMA. 2020;324(8):801.
   PubMed Web of Science ®Google Scholar
• Alaqeel A, Aljuraibah F, Alsuhaibani M, et al. The Impact of COVID-19 pandemic lockdown on the incidence of new-onset type 1 diabetes and ketoacidosis among Saudi children. Front Endocrinol (Lausanne). 2021;12:669302.
   PubMed Web of Science ®Google Scholar
• Pal R, Banerjee M, Yadav U, et al. Clinical profile and outcomes in COVID-19 patients with diabetic ketoacidosis: a systematic review of literature. Diabetes Metab Syndr. 2020 November-December;14(6):1563–1569.
   PubMed Web of Science ®Google Scholar
• Choi WY. Mortality rate of patients with COVID-19 based on underlying health conditions. Disaster Med Public Health Prep. 2021 May;3:1–6.
   Google Scholar
• Corona G, Pizzocaro A, Vena W, et al. Diabetes is most important cause for mortality in COVID-19 hospitalized patients: systematic review and meta-analysis. Rev Endocr Metab Disord. 2021 Jun;22(2):275–296.
   PubMed Web of Science ®Google Scholar
• Mahamat-Saleh Y, Fiolet T, Rebeaud ME, et al. Diabetes, hypertension, body mass index, smoking and COVID-19-related mortality: a systematic review and meta-analysis of observational studies. BMJ Open. 2021 Oct 25;11(10):e052777.
   PubMed Web of Science ®Google Scholar
• Holman N, Knighton P, Kar P, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2020 Oct;8(10):823–833.
   PubMed Web of Science ®Google Scholar
• Boddu SK, Aurangabadkar G, Kuchay MS. New onset diabetes, type 1 diabetes and COVID-19. Diabetes Metab Syndr. 2020 November-Decenber;14(6):2211–2217.
   PubMed Web of Science ®Google Scholar
• Rubino F, Amiel SA, Zimmet P, et al. New-Onset Diabetes in Covid-19. N Engl J Med. 2020 Aug 20;383(8):789–790.
   PubMed Web of Science ®Google Scholar
• Wu CT, Lidsky PV, Xiao Y, et al. SARS-CoV-2 infects human pancreatic beta cells and elicits beta cell impairment. Cell Metab. 2021 Aug 3;33(8):1565–1576 e5.
   PubMed Web of Science ®Google Scholar
• Tang X, Uhl S, Zhang T, et al. SARS-CoV-2 infection induces beta cell transdifferentiation. Cell Metab. 2021 Aug 3;33(8):1577–1591 e7.
   PubMed Web of Science ®Google Scholar
• Yang L, Han Y, Nilsson-Payant BE, et al. A human pluripotent stem cell-based platform to study SARS-CoV-2 tropism and model virus infection in human cells and organoids. Cell Stem Cell. 2020 Jul 2;27(1):125–136 e7.
   PubMed Web of Science ®Google Scholar
• Liu F, Long X, Zhang B, et al. ACE2 expression in pancreas may cause pancreatic damage after SARS-CoV-2 infection. Clin Gastroenterol Hepatol. 2020 Aug;18(9):2128–2130 e2.
   PubMed Web of Science ®Google Scholar
• Jackson CB, Farzan M, Chen B, et al. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol. 2022;23(1):3–20.
   PubMed Web of Science ®Google Scholar
• Tang X, Yang M, Duan Z, et al. Transferrin receptor is another receptor for SARS-CoV-2 entry. Cold Spring Harbor Laboratory; 2020.
   Google Scholar
• Szlachcic WJ, Dabrowska A, Milewska A, et al. SARS-CoV-2 infects an in vitro model of the human developing pancreas through endocytosis. iScience. 2022;25(7):104594.
   PubMed Web of Science ®Google Scholar
• Chow KY, Yeung YS, Hon CC, et al. Adenovirus-mediated expression of the C-terminal domain of SARS-CoV spike protein is sufficient to induce apoptosis in Vero E6 cells. FEBS Lett. 2005 Dec 19;579(30):6699–6704.
   PubMed Web of Science ®Google Scholar
• Gavkare AM, Nanaware N, Rayate AS, et al. COVID-19 associated diabetes mellitus: a review. World J Diabetes. 2022 Sep 15;13(9):729–737.
   PubMed Web of Science ®Google Scholar
• Craig ME, Kim KW, Isaacs SR, et al. Early-life factors contributing to type 1 diabetes. Diabetologia. 2019 Oct;62(10):1823–1834.
   PubMed Web of Science ®Google Scholar
• Corrao S, Pinelli K, Vacca M, et al. Type 2 diabetes mellitus and COVID-19: a narrative review. Front Endocrinol (Lausanne). 2021;12:609470.
   PubMedGoogle Scholar
• Bloomgarden ZT. Inflammation and insulin resistance. Diabetes Care. 2003;26(5):1619–1623.
   PubMed Web of Science ®Google Scholar
• Nerup J, Mandrup-Poulsen T, Molvig J, et al. Mechanisms of pancreatic beta-cell destruction in type I diabetes. Diabetes Care. 1988;Nov-Dec;11(Suppl 1):16–23.
   Google Scholar
• Reiterer M, Rajan M, Gomez-Banoy N, et al. Hyperglycemia in acute COVID-19 is characterized by insulin resistance and adipose tissue infectivity by SARS-CoV-2. Cell Metab. 2021 Dec 7;33(12):2484.
   PubMed Web of Science ®Google Scholar
• Singh AK, Khunti KCOVID-19. and Diabetes. Annu Rev Med. 2022;73(1):129–147.
   PubMedGoogle Scholar
• Lima-Martínez MM, Carrera Boada C, Madera-Silva MD, et al. COVID-19 y diabetes mellitus: una relación bidireccional. Clínica e Investigación en Arteriosclerosis. 2021 [2021 May 01];33(3):151–157.
   PubMed Web of Science ®Google Scholar
• Shenoy A, Ismaily M, Bajaj M. Diabetes and covid-19: a global health challenge. BMJ Open Diabetes Res Care. 2020;8(1):e001450.
   PubMed Web of Science ®Google Scholar
• Barron E, Bakhai C, Kar P, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol. 2020 Oct;8(10):813–822.
   PubMed Web of Science ®Google Scholar
• Gregory JM, Slaughter JC, Duffus SH, et al. COVID-19 severity is tripled in the diabetes community: a prospective analysis of the pandemic’s impact in type 1 and type 2 diabetes. Diabetes Care. 2021 Feb;44(2):526–532.
   PubMed Web of Science ®Google Scholar
• Codo AC, Davanzo GG, Monteiro LB, et al. Elevated glucose levels favor SARS-CoV-2 infection and monocyte response through a HIF-1alpha/glycolysis-dependent axis. Cell Metab. 2020 Sep 1;32(3):498–499.
   PubMed Web of Science ®Google Scholar
• Cromer SJ, Colling C, Schatoff D, et al. Newly diagnosed diabetes vs. pre-existing diabetes upon admission for COVID-19: associated factors, short-term outcomes, and long-term glycemic phenotypes. J Diabetes Complications. 2022 Apr;36(4):108145.
   PubMed Web of Science ®Google Scholar
• French G, Hulse M, Nguyen D, et al. Impact of hospital strain on excess deaths during the COVID-19 pandemic - United States, July 2020-July 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 19;70(46):1613–1616.
   PubMed Web of Science ®Google Scholar
• Patel SY, McCoy RG, Barnett ML, et al. Diabetes Care and glycemic control during the COVID-19 pandemic in the United States. JAMA Intern Med. 2021;181(10):1412.
   PubMed Web of Science ®Google Scholar
• Aubert CE, Henderson JB, Kerr EA, et al. Type 2 Diabetes management, control and outcomes during the COVID-19 pandemic in older US Veterans: an Observational Study. J Gen Intern Med. 2022;37(4):870–877.
   PubMedGoogle Scholar
• Biamonte E, Pegoraro F, Carrone F, et al. Weight change and glycemic control in type 2 diabetes patients during COVID-19 pandemic: the lockdown effect. Endocrine. 2021;72(3):604–610.
   PubMed Web of Science ®Google Scholar
• Ceconi V, Barbi E, Tornese G. Glycemic control in type 1 diabetes mellitus and COVID ‐19 lockdown: what comes after a “quarantine”? J Diabetes. 2020;12(12):946–948.
   PubMed Web of Science ®Google Scholar
• Gayoso M, Lim WY, Mulekar MS, et al. Effect of Covid-19 quarantine on diabetes Care in Children. Clin Diabetes Endocrinol. 2021;7:1.
   PubMedGoogle Scholar
• Patel MR, Zhang G, Leung C, et al. Impacts of the COVID-19 pandemic on unmet social needs, self-care, and outcomes among people with diabetes and poor glycemic control. Prim Care Diabetes. 2022;16(1):57–64.
   PubMed Web of Science ®Google Scholar
• Watson OJ, Barnsley G, Toor J, et al. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis. 2022 Sep;22(9):1293–1302.
   PubMed Web of Science ®Google Scholar
• Anand P, Stahel VP. The safety of Covid-19 mRNA vaccines: a review. Patient Saf Surg. 2021;15:1.
   PubMed Web of Science ®Google Scholar
• Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med. 2021;385(12):1078–1090.
   PubMed Web of Science ®Google Scholar
• Ø K, Hovi P, Husby A, et al. SARS-CoV-2 vaccination and myocarditis in a Nordic cohort study of 23 million residents. JAMA Cardiol. 2022;7(6):600.
   PubMed Web of Science ®Google Scholar
• Marzi M, Vakil MK, Bahmanyar Met al. 2022. Paxlovid: Mechanism of Action, Synthesis, and in silico Study. Bio Med Res Int. 2022;1–16. DOI:10.1155/2022/7341493.
   Google Scholar
• Emergency Use Authorization (EUA) for Paxlovid (nirmatrelvir tablets co-packaged with ritonavir tablets) Center for Drug Evaluation and Research (CDER) Review. https://www.fda.gov/media/155194/download
   Google Scholar
• Remdesivir Children's Hospital of Philadelphia. Available from: https://www.chop.edu/clinical-pathway/covid-disease-remdesivir#:~:text=The%20mechanism%20of%20action%20of,reported%20to%20date%2C%20including%20omicron
   Google Scholar
• Negahdaripour, M. Post-COVID-19 Hyperglycemia: A Concern in Selection of Therapeutic Regimens Iran J Med Sci. 2021;46(4):235–236. DOI:10.30476/ijms.2021.47666
   Google Scholar
• FACT SHEET FOR HEALTHCARE PROVIDERS: EMERGENCY USE AUTHORIZATION FOR BEBTELOVIMAB. Available from: https://www.fda.gov/media/156152/download#:~:text=12.1%20Mechanism%20of%20Action,-Bebtelovimab%20is%20a&text=Bebtelovimab%20binds%20the%20spike%20protein,(0.056%20mcg%2FmL )
   Google Scholar
• Molnupiravir Oral Treatment of COVID-19. Available from: https://www.fda.gov/media/154421/download
   Google Scholar
• Lee HJ, Sajan A, Tomer Y. Hyperglycemic emergencies associated with COVID-19 vaccination: a case series and discussion. J Endocr Soc. 2021 Nov 1;5(11):bvab141.
   PubMed Web of Science ®Google Scholar
• Yano M, Morioka T, Natsuki Y, et al. New-onset Type 1 Diabetes after COVID-19 mRNA vaccination. Intern Med. 2022 Apr 15;61(8):1197–1200.
   PubMed Web of Science ®Google Scholar
• Samuel SM, Varghese E, Triggle CR, et al. COVID-19 vaccines and hyperglycemia-is there a need for postvaccination surveillance? Vaccines (Basel). 2022 16;10(3):Mar.
   Web of Science ®Google Scholar
• Chemaitelly H, Yassine HM, Benslimane FM, et al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat Med. 2021;27(9):1614–1621.
   PubMed Web of Science ®Google Scholar
• Marfella R, Sardu C, D’Onofrio N, et al. Glycaemic control is associated with SARS-CoV-2 breakthrough infections in vaccinated patients with type 2 diabetes. Nat Commun. 2022;13:1.
   PubMed Web of Science ®Google Scholar
• COVIDIAB registry. https://covidiab.e-dendrite.com/
   Google Scholar